A Revolution <br> in Heart Valve Replacement<i class=">

A Revolution
in Heart Valve Replacement


Xeltis is a clinical-stage medical device company developing the first heart valves and blood vessels enabling cardiovascular restoration.

Xeltis’ breakthrough technology platform, RestoreX, comprises bioabsorbable devices that, after implantation, enable Endogenous Tissue Restoration (ETR) of the heart valve or blood vessel they replace.


Endogenous Tissue Restoration



Endogenous Tissue Restoration (ETR) is a novel therapeutic approach, enabling the patient’s own tissue to restore complex cardiac parts within the body.

The porous structure of a Xeltis bioabsorbable device enables cardiovascular restoration once implanted. It harnesses the body’s natural healing process to pervade it with new healthy tissue and to take over functionality.


Key Benefits


Xeltis devices are designed to absorb over time, leaving patients with a new, healthy, functioning heart valve or blood vessel


As Xeltis devices are designed to get bioabsorbed, complications caused by foreign material permanently remaining in the body may potentially be reduced


Potential to overcome limitations of current replacement options:
• Reduce risk of complications
• Reduce risk of repeated surgeries
• Reduce risk of long-term medication


Xeltis devices may therefore help reduce the disease burden for patients and the overall costs to the healthcare system

Clinical Milestones

Feasibility studies of RestoreX technology with pediatric patients completed two-years follow-up.

Xeltis pediatric pulmonary valve, its first commercial product, is in clinical trials.

Xeltis aortic valve is in pre-clinical trials stage.

Nobel Prize Awarded Science

RestoreX bioabsorbable cardiovascular technology is based on Nobel Prize awarded science of supramolecular chemistry by Jean-Marie Lehn – Xeltis Scientific Advisor.

The Future
of Heart Valve

CTO and co-Founder Martijn
Cox takes you into the lab
for a closer look at Xeltis. WATCH THE VIDEO